On March 25, 2026, Immix Biopharma, Inc. announced that it has entered into Amendment No. 1 to its At The Market Offering Agreement with Citizens JMP Securities, LLC. This amendment allows the company to offer and sell shares of its common stock, with an aggregate offering price of up to $100 million. The offering will be conducted through Citizens JMP Securities, acting as the sales agent, and will utilize the company's existing effective registration statement on Form S-3. The amendment is expected to enhance the company's liquidity position by providing access to capital as needed, while also allowing for flexibility in the timing and amount of stock sales. The company will pay a commission of 3% on the gross sales proceeds from any shares sold under this agreement. This strategic move is aimed at bolstering the company's financial resources to support its ongoing operations and growth initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.